276 related articles for article (PubMed ID: 32771992)
1. Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells.
Chen H; Chen Y; Deng M; John S; Gui X; Kansagra A; Chen W; Kim J; Lewis C; Wu G; Xie J; Zhang L; Huang R; Liu X; Arase H; Huang Y; Yu H; Luo W; Xia N; Zhang N; An Z; Zhang CC
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32771992
[TBL] [Abstract][Full Text] [Related]
2. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer.
Zeller T; Münnich IA; Windisch R; Hilger P; Schewe DM; Humpe A; Kellner C
Front Immunol; 2023; 14():1240275. PubMed ID: 37781391
[TBL] [Abstract][Full Text] [Related]
3. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8
Kim A; Han CJ; Driver I; Olow A; Sewell AK; Zhang Z; Ouyang W; Egen JG; Yu X
J Immunol; 2019 Aug; 203(4):1076-1087. PubMed ID: 31253728
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo.
Koh CY; Blazar BR; George T; Welniak LA; Capitini CM; Raziuddin A; Murphy WJ; Bennett M
Blood; 2001 May; 97(10):3132-7. PubMed ID: 11342440
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for RIFIN-mediated activation of LILRB1 in malaria.
Harrison TE; Mørch AM; Felce JH; Sakoguchi A; Reid AJ; Arase H; Dustin ML; Higgins MK
Nature; 2020 Nov; 587(7833):309-312. PubMed ID: 32650338
[TBL] [Abstract][Full Text] [Related]
6. Impact of the NK cell receptor LIR-1 (ILT-2/CD85j/LILRB1) on cytotoxicity against multiple myeloma.
Heidenreich S; Zu Eulenburg C; Hildebrandt Y; Stübig T; Sierich H; Badbaran A; Eiermann TH; Binder TM; Kröger N
Clin Dev Immunol; 2012; 2012():652130. PubMed ID: 22844324
[TBL] [Abstract][Full Text] [Related]
7. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F; André P; Spee P; Zahn S; Anfossi N; Gauthier L; Capanni M; Ruggeri L; Benson DM; Blaser BW; Della Chiesa M; Moretta A; Vivier E; Caligiuri MA; Velardi A; Wagtmann N
Blood; 2009 Sep; 114(13):2667-77. PubMed ID: 19553639
[TBL] [Abstract][Full Text] [Related]
9. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.
Guo Y; Feng X; Jiang Y; Shi X; Xing X; Liu X; Li N; Fadeel B; Zheng C
Oncotarget; 2016 Jul; 7(30):48360-48374. PubMed ID: 27356741
[TBL] [Abstract][Full Text] [Related]
10. Effect of cytomegalovirus infection and leukocyte immunoglobulin like receptor B1 polymorphisms on receptor expression in peripheral blood mononuclear cells.
Cadena-Mota S; Monsiváis-Urenda A; Salgado-Bustamante M; Monjarás-Ávila C; Bernal-Silva S; Aranda-Romo S; Noyola DE
Microbiol Immunol; 2018 Dec; 62(12):755-762. PubMed ID: 30461037
[TBL] [Abstract][Full Text] [Related]
11. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma.
Fan J; Li J; Han J; Zhang Y; Gu A; Song F; Duan J; Yin D; Wang L; Yi Y
Mol Immunol; 2021 Aug; 136():82-97. PubMed ID: 34098344
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cell profiles in recurrent pregnancy loss: Increased expression and positive associations with TACTILE and LILRB1.
Habets DHJ; Schlütter A; van Kuijk SMJ; Spaanderman MEA; Al-Nasiry S; Wieten L
Am J Reprod Immunol; 2022 Nov; 88(5):e13612. PubMed ID: 36004818
[TBL] [Abstract][Full Text] [Related]
13. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.
Barkal AA; Weiskopf K; Kao KS; Gordon SR; Rosental B; Yiu YY; George BM; Markovic M; Ring NG; Tsai JM; McKenna KM; Ho PY; Cheng RZ; Chen JY; Barkal LJ; Ring AM; Weissman IL; Maute RL
Nat Immunol; 2018 Jan; 19(1):76-84. PubMed ID: 29180808
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade.
Godal R; Bachanova V; Gleason M; McCullar V; Yun GH; Cooley S; Verneris MR; McGlave PB; Miller JS
Biol Blood Marrow Transplant; 2010 May; 16(5):612-21. PubMed ID: 20139023
[TBL] [Abstract][Full Text] [Related]
15. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
17. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
18. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages.
Zeller T; Lutz S; Münnich IA; Windisch R; Hilger P; Herold T; Tahiri N; Banck JC; Weigert O; Moosmann A; von Bergwelt-Baildon M; Flamann C; Bruns H; Wichmann C; Baumann N; Valerius T; Schewe DM; Peipp M; Rösner T; Humpe A; Kellner C
Front Immunol; 2022; 13():929339. PubMed ID: 36389667
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
[TBL] [Abstract][Full Text] [Related]
20.
Guo X; Mahlakõiv T; Ye Q; Somanchi S; He S; Rana H; DiFiglia A; Gleason J; van der Touw W; Hariri R; Zhang X
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
